Adiponectin receptor activation inhibits prostate cancer xenograft growth.
Lisa K Philp, Anja Rockstroh, Melanie Lehman, Martin C Sadowski, Nenad Bartonicek, John D Wade, Laszlo Otvos, Colleen C Nelson
Endocrine Related Cancer | Published : 2020
Adiponectin is an adipokine originally identified as dysregulated in obesity, with a key role in insulin sensitisation and in maintaining systemic energy balance. However, adiponectin is progressively emerging as having aberrant signalling in multiple disease states, including prostate cancer (PCa). Circulating adiponectin is lower in patients with PCa than in non-malignant disease, and inversely correlates with cancer severity. More severe hypoadiponectinemia is observed in advanced PCa than in organ-confined disease. Given the crossover between adiponectin signalling and several cancer hallmark pathways that influence PCa growth and progression, we hypothesised that targeting dysregulated ..View full abstract